Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

BACKGROUND: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. CASE: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC...

Descripción completa

Detalles Bibliográficos
Autores principales: Santin, Alessandro D., Bellone, Stefania, Buza, Natalia, Schwartz, Peter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175991/
https://www.ncbi.nlm.nih.gov/pubmed/28018954
http://dx.doi.org/10.1016/j.gore.2016.12.003
_version_ 1782484750949154816
author Santin, Alessandro D.
Bellone, Stefania
Buza, Natalia
Schwartz, Peter E.
author_facet Santin, Alessandro D.
Bellone, Stefania
Buza, Natalia
Schwartz, Peter E.
author_sort Santin, Alessandro D.
collection PubMed
description BACKGROUND: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. CASE: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC overexpressing HER2/neu at 3 + level by IHC treated with the anti-HER2/neu antibody-drug-conjugate (ADC) trastuzumab-emtansine (TDM-1-Kadcyla-Genentech/Roche). She experienced a remarkable clinical response to TDM-1 with a complete resolution of a large metastatic, radiation/chemotherapy resistant tumor deposit in her abdominal wall muscle confirmed by multiple CAT scans and a prolonged systemic control of her disease. CONCLUSION: TDM-1 may represent a novel treatment option for recurrent/metastatic HER2/neu-positive USC patients refractory to salvage-treatment.
format Online
Article
Text
id pubmed-5175991
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-51759912016-12-23 Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1) Santin, Alessandro D. Bellone, Stefania Buza, Natalia Schwartz, Peter E. Gynecol Oncol Rep Case Report BACKGROUND: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. CASE: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC overexpressing HER2/neu at 3 + level by IHC treated with the anti-HER2/neu antibody-drug-conjugate (ADC) trastuzumab-emtansine (TDM-1-Kadcyla-Genentech/Roche). She experienced a remarkable clinical response to TDM-1 with a complete resolution of a large metastatic, radiation/chemotherapy resistant tumor deposit in her abdominal wall muscle confirmed by multiple CAT scans and a prolonged systemic control of her disease. CONCLUSION: TDM-1 may represent a novel treatment option for recurrent/metastatic HER2/neu-positive USC patients refractory to salvage-treatment. Elsevier 2016-12-14 /pmc/articles/PMC5175991/ /pubmed/28018954 http://dx.doi.org/10.1016/j.gore.2016.12.003 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Santin, Alessandro D.
Bellone, Stefania
Buza, Natalia
Schwartz, Peter E.
Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
title Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
title_full Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
title_fullStr Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
title_full_unstemmed Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
title_short Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
title_sort regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing her2/neu with trastuzumab emtansine (tdm-1)
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175991/
https://www.ncbi.nlm.nih.gov/pubmed/28018954
http://dx.doi.org/10.1016/j.gore.2016.12.003
work_keys_str_mv AT santinalessandrod regressionofmetastaticradiationchemotherapyresistantuterineserouscarcinomaoverexpressingher2neuwithtrastuzumabemtansinetdm1
AT bellonestefania regressionofmetastaticradiationchemotherapyresistantuterineserouscarcinomaoverexpressingher2neuwithtrastuzumabemtansinetdm1
AT buzanatalia regressionofmetastaticradiationchemotherapyresistantuterineserouscarcinomaoverexpressingher2neuwithtrastuzumabemtansinetdm1
AT schwartzpetere regressionofmetastaticradiationchemotherapyresistantuterineserouscarcinomaoverexpressingher2neuwithtrastuzumabemtansinetdm1

Ejemplares similares